1. Muraki S, Oka H, Akune T, et al. Prevalence of radiographic knee osteoarthritis and its association with knee pain in the elderly of Japanese population-based cohorts: the ROAD study. Osteoarthritis Cartilage. 2009; 17:1137–43.
Article
2. Edwards RR, Fillingim RB, Ness TJ. Age-related differences in endogenous pain modulation: a comparison of diffuse noxious inhibitory controls in healthy older and younger adults. Pain. 2003; 101:155–65.
Article
3. Cole LJ, Farrell MJ, Gibson SJ, et al. Age-related differences in pain sensitivity and regional brain activity evoked by noxious pressure. Neurobiol Aging. 2010; 31:494–503.
Article
4. Jimenez-Andrade JM, Mantyh WG, Bloom AP, et al. The effect of aging on the density of the sensory nerve fiber in-nervation of bone and acute skeletal pain. Neurobiol Aging. 2012; 33:921–32.
Article
5. Gaus S, Moriwaki K, Suyama H, et al. Capsaicin treatment inhibits osteopenia and heat hyperalgesia induced by chronic constriction injury to the sciatic nerve in rats. Hiroshima J Med Sci. 2003; 52:43–51.
6. Nagae M, Hiraga T, Wakabayashi H, et al. Osteoclasts play a part in pain due to the inflammation adjacent to bone. Bone. 2006; 39:1107–15.
Article
7. Rogers MJ, Crockett JC, Coxon FP, et al. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011; 49:34–41.
Article
8. Iwamoto J, Takeda T, Sato Y, et al. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis. Clin Rheumatol. 2004; 23:383–9.
9. Corrado A, Santoro N, Cantatore FP. Extraskeletal effects of bisphosphonates. Joint Bone Spine. 2007; 74:32–8.
Article
10. Ceponis A, Waris E, Monkkonen J, et al. Effects of low-dose, noncytotoxic, intraarticular liposomal clodronate on development of erosions and proteoglycan loss in estab-lished antigen-induced arthritis in rabbits. Arthritis Rheum. 2001; 44:1908–16.
11. Kim S, Seiryu M, Okada S, et al. Analgesic effects of the non-nitrogen-containing bisphosphonates etidronate and clodronate, independent of antiresorptive effects on bone. Eur J Pharmacol. 2013; 699:14–22.
Article
12. Fujita T, Ohue M, Fujii Y, et al. Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance. J Bone Miner Metab. 2009; 27:234–9.
Article
13. Pappagallo M, Breuer B, Lin HM, et al. A pilot trial of intravenous pamidronate for chronic low back pain. Pain. 2014; 155:108–17.
Article
14. Pappagallo M, Breuer B, Schneider A, et al. Treatment of chronic mechanical spinal pain with intravenous pamidronate: a review of medical records. J Pain Symptom Manage. 2003; 26:678–83.
Article
15. Ohtori S, Akazawa T, Murata Y, et al. Risedronate de-creases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures. J Clin Neurosci. 2010; 17:209–13.
Article
16. Bonabello A, Galmozzi MR, Canaparo R, et al. Long-term analgesic effect of clodronate in rodents. Bone. 2003; 33:567–74.
Article
17. Iolascon G, Gimigliano F, Malavolta N, et al. Effectiveness of teriparatide treatment on back pain-related functional limitations in individuals affected by severe osteoporosis: a prospective pilot study. Clin Cases Miner Bone Metab. 2012; 9:161–5.
18. Ritchie RO. How does human bone resist fracture? Ann N Y Acad Sci. 2010; 1192:72–80.
Article
19. Hadji P, Zanchetta JR, Russo L, et al. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporos Int. 2012; 23:2141–50.
Article
20. Dobolyi A, Ueda H, Uchida H, et al. Anatomical and phys-iological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception. Proc Natl Acad Sci U S A. 2002; 99:1651–6.
Article
21. Chhabra H, Malhotra R, Marwah S, et al. An observational study to assess back pain in patients with severe osteoporosis treated with teriparatide versus antiresorptives: An Indian subpopulation analysis. Indian J Endocrinol Metab. 2015; 19:483–90.
22. Fischer JA, Tobler PH, Kaufmann M, et al. Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary. Proc Natl Acad Sci U S A. 1981; 78:7801–5.
Article
23. Lyritis GP, Ioannidis GV, Karachalios T, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain. 1999; 15:284–9.
Article
24. Overman RA, Borse M, Gourlay ML. Salmon calcitonin use and associated cancer risk. Ann Pharmacother. 2013; 47:1675–84.
Article
25. Musgrave DS, Vogt MT, Nevitt MC, et al. Back problems among postmenopausal women taking estrogen replacement therapy: the study of osteoporotic fractures. Spine (Phila Pa 1976). 2001; 26:1606–12.
26. Scharla S, Oertel H, Helsberg K, et al. Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration. Curr Med Res Opin. 2006; 22:2393–402.
Article
27. Gennari C, Chierichetti MS, Gonnelli S, et al. Migraine prophylaxis with salmon calcitonin: a cross-over double-blind, placebo-controlled study. Headache. 1986; 26:13–6.
Article
28. Micieli G, Cavallini A, Martignoni E, et al. Effectiveness of salmon calcitonin nasal spray preparation in migraine treatment. Headache. 1988; 28:196–200.
Article
29. Iwamoto J, Makita K, Sato Y, et al. Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis. Osteoporos Int. 2011; 22:2735–42.
Article
30. Songpatanasilp T, Mumtaz M, Chhabra H, et al. Back pain in patients with severe osteoporosis on teriparatide or anti-resorptives: a prospective observational study in a multieth-nic population. Singapore Med J. 2014; 55:493–501.
Article